RxDoctor Payments Data

Melissa Lane

Psychiatric/Mental Health · Stroudsburg, PANPI 1336905850

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 67 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$344
  • Teva Pharmaceuticals USA, Inc.$240
  • Neurocrine Biosciences, Inc.$187
  • Takeda Pharmaceuticals U.S.A., Inc.$100
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$96
  • Johnson & Johnson$90
  • plus $243 from 6 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,301 in reported general payments places this provider in the 65th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,627
Medicare patients
49
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$191,052
AustedoDeutetrabenazine16$69,500
VraylarCariprazine Hcl25$50,951
RexultiBrexpiprazole27$38,025
TrintellixVortioxetine Hydrobromide21$15,767
BelsomraSuvorexant11$8,057
Paliperidone ErPaliperidone18$6,027
Clomipramine Hcl23$4,971
Aripiprazole76$3,683
Vilazodone Hcl34$2,336
Ziprasidone Hcl38$2,281
Zolpidem Tartrate ErZolpidem Tartrate33$1,810
Quetiapine Fumarate101$1,387
Venlafaxine Hcl ErVenlafaxine Hcl121$1,310
Clonazepam227$1,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$187$191,05223 claims
Teva Pharmaceuticals USA, Inc.Austedo$240$69,50016 claims
AbbVieVraylar$15$50,95125 claims
Otsuka America Pharmaceutical, Inc.Rexulti$82$38,02527 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$100$15,76721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →